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FoxO1 integrates multiple metabolic pathways. Nu-
trient levels modulate FoxO1 acetylation, but the
functional consequences of this posttranslational
modification are unclear. To answer this question,
we generated mice bearing alleles that encode con-
stitutively acetylated and acetylation-defective
FoxO1 proteins. Homozygosity for an allele mim-
icking constitutive acetylation (Foxo1KQ/KQ) results
in embryonic lethality due to cardiac and angiogen-
esis defects. In contrast, mice homozygous for a
constitutively deacetylated Foxo1 allele (Foxo1KR/KR)
display a unique metabolic phenotype of impaired
insulin action on hepatic glucose metabolism but
decreased plasma lipid levels and low respiratory
quotient that are consistent with a state of preferen-
tial lipid usage. Moreover, Foxo1KR/KR mice show a
dissociation between weight gain and insulin resis-
tance in predisposing conditions (high fat diet, dia-
betes, and insulin receptor mutations), possibly due
to decreased cytokine production in adipose tissue.
Thus, acetylation inactivates FoxO1 during nutrient
excess whereas deacetylation selectively potenti-
ates FoxO1 activity, protecting against excessive
catabolism during nutrient deprivation.
INTRODUCTION
The discovery of FoxO transcription factors as distal effectors of
insulin signaling marks a watershed in metabolic research (Accili
and Arden, 2004; Kimura et al., 1997). A burgeoning consensusCell Mindicates that FoxOs (especially FoxO1) regulate liver glucose
production (Dong et al., 2008; Matsumoto et al., 2007; Nakae
et al., 2001a, 2002), hypothalamic neuropeptide synthesis (Kita-
mura et al., 2006) and processing (Plum et al., 2009), adipocyte
and myoblast differentiation (Hribal et al., 2003; Nakae et al.,
2003), and pancreatic b-cell turnover and function (Kitamura
et al., 2002, 2005; Nakae et al., 2002; Okamoto et al., 2006).
FoxO proteins link the metabolic state of the organism to
cellular gene expression, allowing target tissues to adopt a
posture that reflects nutrient availability (FoxO off) or deprivation
(FoxO on). As with other nutrient and stress sensors (Allen-
Jennings et al., 2001), FoxOs are regulated via posttransla-
tional modifications. Akt-dependent phosphorylation inactivates
FoxOs by causing their nuclear exclusion. In addition, FoxOs are
acetylated by Cbp and deacetylated by Class I-II and Class III
(NAD-dependent) deacetylases (Brunet et al., 2004; Daitoku
et al., 2004; van der Horst et al., 2004).
SirT1, a Class III deacetylase, affects lifespan in lower eukary-
otes and requires the FoxO ortholog daf-16 for this effect (Imai
et al., 2000; Tissenbaum and Guarente, 2001). Because Sirt1
activation has beneficial effects on mammalian metabolism
(Banks et al., 2008; Pfluger et al., 2008), including improvements
in glucose tolerance and decreased hepatic glucose production,
we proposed that it acts by promoting FoxO1 deacetylation
(Banks et al., 2008). There has been considerable interest in
understanding the effects of FoxO acetylation. At the cellular
level, it can be shown that acetylation affects FoxO trafficking
(Brunet et al., 2004; Frescas et al., 2005; Kitamura et al., 2005)
and DNA binding (Daitoku et al., 2004; Kitamura et al., 2005).
However, the phenotypic consequences of this posttranslational
modification remain unclear (Daitoku et al., 2004; Kitamura et al.,
2005;Motta et al., 2004), owing partly to the difficulty of conduct-
ing rigorous quantitative assessments of in vivo acetylation, the
interplay between acetylation, phosphorylation and protein
stability (Qiang et al., 2010), and the intrinsic shortcomings ofetabolism 14, 587–597, November 2, 2011 ª2011 Elsevier Inc. 587
Figure 1. FoxO1 Acetylation and Localization
(A) Immunoblot analysis of FoxO1 acetyllysine content in epididymal adipose
tissue extracts from mice subjected to fasting and re-refeeding.
(B) Fluorescence microscopy of primary mouse hepatocytes transduced with
FoxO1-GFP-WT, -KR, or -KQ adenoviruses and maintained in serum-free
medium (upper panel) or incubated with insulin (lower panel). We show
representative images.
(C and D) Immunoblotting analysis of FoxO1 content in nuclear and cytosolic
fractions isolated from epididymal adipose tissue extracts of fasted (C) or refed
(D) wild-type (WT) or Foxo1KR/KR (KR) animals. We used nucleophosmin (NPM)
or tubulin as markers of cellular fractions in (C) and Hdac1 or b-actin in (D).
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In Vitro Effects of FoxO1 Acetylationassaying FoxO function in cultured cells. To answer this ques-
tion, we generated two mouse models by introducing targeted
mutations in the Foxo1 locus that yield alleles encoding
either constitutively acetylated or acetylation-defective mutant
FoxO1. In this study, we report that appropriate regulation of
FoxO1 by acetylation is essential for survival. We show that acet-
ylation of FoxO1 controls development, energy balance, and
nutrient homeostasis. We link these phenotypes with a selective588 Cell Metabolism 14, 587–597, November 2, 2011 ª2011 Elsevierregulation of gene expression that possibly reflects metabolic
changes in response to prolonged fasting or calorie restriction.
RESULTS
Generation of Foxo1 Knock-in Alleles
FoxO1 acetylation is physiologically regulated by nutritional
status: it decreases when animals are fasted, and it increases
after refeeding (Figure 1A). We have previously identified seven
lysine acetylation sites at amino acid residues 219, 242, 245,
259, 262, 271, and 291 (Kitamura et al., 2005; Qiang et al.,
2010). To understand the physiologic function of FoxO1 acetyla-
tion, we used homologous recombination in embryonic stem
cells to generate mice bearing recombinant Foxo1 alleles in
which the endogenous exon 2 has been replacedwith amodified
exon 2 encoding either a constitutively acetylated allele or a
constitutively deacetylated allele (Figure S1 available online).
We refer to the former as Foxo1KQ allele (in which lysine has
been replaced by glutamine) and to the latter as Foxo1KR allele
(in which lysine has been replaced by arginine).
We analyzed the subcellular distribution of KQ and KR FoxO1
by transduction of adenoviruses encoding the two mutants as
GFP fusion proteins in primary mouse hepatocytes. In response
to insulin, wild-type FoxO1 redistributes from the nucleus to the
cytoplasm. We observed that the KQmutant was predominantly
cytoplasmic, whereas the KRmutant was predominantly nuclear
(Figure 1B). Consistent with these data, we observed increased
FoxO1 immunoreactivity in nuclear fractions isolated from
adipocytes of Foxo1KR/KR mice compared to wild-type litter-
mates and decreased immunoreactivity in cytoplasmic fractions
(Figure 1C). This pattern persisted in refed animals, consistent
with impaired nuclear exclusion of the KR mutant (Figure 1D).
These findings indicate that the Foxo1KR allele confers gain of
function, whereas the Foxo1KQ allele confers loss of function.
Embryonic Lethality in Foxo1KQ/KQ Mice Due
to Defective Vasculogenesis
Foxo1KQ/+ mice are viable and fertile, but no viable homozygous
offspring resulted from the intercrossing of Foxo1KQ/+ mice, as
determined by genotyping of litters on postnatal day (P) 12
(Table S1). Between embryonic (E) day 9.5 and E11.5, we
observed the expected Mendelian frequency of genotypes
(c2 = 4.10); however, all homozygous mutants were abnormal.
At E11.5, all Foxo1KQ/KQ embryos (n = 3) lacked a heartbeat
and were deteriorating (Figure 2A). At E10.5, the single
Foxo1KQ/KQ embryo that we recovered had a heartbeat but
showed significant growth retardation and an enlarged pericar-
dium (Figure 2B). At E9.5,Foxo1KQ/KQ embryos had a hypoplastic
first branchial arch (I), and the second branchial arch (II) was
either absent or hypoplastic; they also displayed a distended
heart and an expanded atrioventricular canal (n = 8/10 assessed)
(Figures 2C and 2D). Histological sections from a stage-matched
Foxo1KQ/KQ and Foxo1+/+ pair further demonstrated the ex-
panded atrioventricular canal and revealed disorganized trabe-
culi within the ventricle (Figures 2E and 2F).
Based on the defective angiogenesis and vascular remodeling
in Foxo1/ mice (Furuyama et al., 2004), we determined the
extent of vascularization in Foxo1KQ/KQ mutants using whole-
mount immunostaining with the endothelial-specific marker,Inc.
Figure 2. Embryonic Lethality in Mice Homozygous for the Foxo1KQ/KQ Mutation
(A and B) Microphotographs of Foxo1+/+ and Foxo1KQ/KQ embryos at E10.5 and E11.5.
(C and D) Microphotographs of E9.5 embryos showing first (I) and second branchial arch (II), as well as atrioventricular canal (AVC) and ventricle (V). Arrow in D
indicates the distended AVC in the mutant.
(E and F) Histological sections of E9.5 embryos across the AVC (arrows) and ventricle.
(G–L) Whole-mount PECAM-1 immunostaining with details of the aortic arch arteries in the head (arrowheads in (I), missing in (J) and the dorsal aorta (arrows)
in the tail region (K and L) of a Foxo1+/+ (G, I, and K) and Foxo1KQ/KQ embryo (H, J, and L). Asterisks in K and L mark somites, which are smaller in the mutant.
(M and N) Histological sections through the first branchial arch showing dorsal aortae (arrows in M) and the first branchial arch artery (arrowheads in M).
(M’ and N’) Sections through more posterior regions showing paired dorsal aortae (arrows that are distended in the mutant (N’) compared with wild-type (M’).
(O and P) Vascular plexus in the yolk sac in Foxo1KQ/KQ and wild-type embryos shown by immunostaining for PECAM.
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In Vitro Effects of FoxO1 AcetylationPECAM-1 (Figures 2G–2L). The vasculature in the head was
significantly reduced in the Foxo1KQ/KQ compared to wild-type
mice, and the aortic arch arteries could not be resolved in the
mutant (Figures 2I and 2J). Moreover, although the dorsal aorta
appeared to be present in both wild-type and mutant mice, the
Foxo1KQ/KQ embryos displayed an aortic PECAM-1 stainingCell Mpattern that was more evident in the posterior of the embryo
(Figures 2G–2L). Confirmation of the underdeveloped or missing
aortic arch arteries was apparent with histological analyses of
transverse section (Figures 2M and 2N). Sections also showed
minimal development of the dorsal aortae in the head (Figures
2E, 2F, 2M, and 2N) but large, distended dorsal aortae in theetabolism 14, 587–597, November 2, 2011 ª2011 Elsevier Inc. 589
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In Vitro Effects of FoxO1 Acetylationposterior (Figures 2M0 and 2N0). Not noted in Foxo1 null embryos
(Furuyama et al., 2004; Hosaka et al., 2004) was a defect in
somite development that is apparent in Foxo1KQ/KQ embryos
as small and irregular somites (Figures 2K and 2L). Finally, the
vascular plexus in the yolk sac appears to have formed in the
Foxo1KQ/KQmutant (Figures 2O and 2P), but further development
is compromised (data not shown).
Metabolic Characterization of Foxo1KR/KR Mutants
Unlike Foxo1KQ/KQ, Foxo1KR/KR mutants were born at term in
Mendelian ratios and grew normally. Immunoblotting analyses
of FoxO1 immunoprecipitated from liver extracts of 12-wk-old
mice indicated that its acetyllysine content was substantially
decreased, which is consistent with the notion that the seven
mutated amino acid residues account for the bulk of FoxO1
acetylation (Figure S1).
Foxo1KR/KRmice showed normal glucose and insulin levels, as
well as glucose tolerance and insulin tolerance, following 4 hr
fast (data not shown). However, glucose and insulin levels
were significantly increased after 18 hr fast or 4 hr refeeding
(Table S2). Accordingly, under these conditions Foxo1KR/KR
mice showed a 50% increase according to the Homeostatis
Model of Assessment of Insulin Resistance (HOMA-IR), com-
pared to littermate controls (Figure 3A). Given the role of
FoxO1in hepatic glucose production, we subjected Foxo1KR/KR
mice to pyruvate tolerance tests (Matsumoto et al., 2007). They
showed increased glucose levels that were consistent with
increased hepatic glucose production (Figure 3B). Next, we per-
formed hyperinsulinemic euglycemic clamp studies. Consistent
with the slight increases of glucose and insulin, we found
decreased glucose infusion rates (Figure 3C). In addition, rates
of hepatic glucose production in the presence of maximal insulin
concentrations (60 mU/ml) were 2.5-fold higher in Foxo1KR/KR
mice, which is consistent with insulin resistance of hepatic
glucose metabolism even though the difference did not achieve
statistical significance, owing to elevated individual variations
among mice tested (Figure 3D). Whole body glucose uptake
was unchanged, and glycolysis showed a nonsignificant trend
toward reduction (Figure 3E). Several additional parameters
measured during the clamps were normal (Figure S2).
In contrast with the data on glucose and insulin, we observed
a significant decrease of plasma free fatty acids (FFA), triglyc-
eride (TG), and total cholesterol levels, as well as liver TG content
in the refed state (Table S2). Analysis of lipoprotein composition
indicated that the reduction in TG levels was due primarily to
decreased very low-density lipoprotein (VLDL) TG (Figure 3F).
However, the main apoprotein component of VLDL, ApoB, was
expressed at normal levels (data not shown), as was the LDL
receptor (Figure S2), and TG secretion was normal (data not
shown), indicating that the reduction in TG levels is not
secondary to decreased secretion or accelerated clearance
through hepatic LDL receptors. Similar to TG, cholesterol levels
were reduced in all lipoprotein fractions (Figure S2). De novo
lipogenesis, which was measured by incorporating 3H2O into
fatty acids, decreased by  20% in Foxo1KR/KR mice (21.86
versus 27.03 to mmol/g protein/hr).
To determine the contribution of adipose tissue lipolysis to
the observed changes in TG and FFA levels, we measured FFA
suppression during glucose clamps and glycerol release from590 Cell Metabolism 14, 587–597, November 2, 2011 ª2011 Elsevierisolated epididymal fat pads under basal and isoproterenol-stim-
ulated conditions. The former was identical between the two
strains (Figure S2), while the latter was slightly increased in
Foxo1KR/KR mice in the presence of isoproterenol (Figure 3G),
indicating that the lower plasma TG and FFA in mutant mice
are not secondary to decreased adipocyte lipolysis.
Selective Regulation of FoxO1-Dependent Gene
Expression in Foxo1KR/KR Mice
To understand the pathophysiology of the dissociation between
impaired glucose and improved lipid metabolism, we analyzed
gene expression in fasted and refed Foxo1KR/KR mice. In both
conditions, we found 1.5- to 2-fold increases in the expression
of hepatic gluconeogenetic genes, including G6pc, Pck1, and
Pgc1a (Matsumoto et al., 2007; Puigserver et al., 2003) (Fig-
ure 4A). Conversely, we found a 50%–70% decrease of Gck
and a 30% decrease of Pkrl, two key regulators of glycolysis.
These changes dovetail with the decreased sensitivity of hepatic
glucose production (HGP) to insulin suppression and with the
decreased glycolysis observed in the clamps. This concerted
shift to increase glucose production and inhibit glucose break-
down was specific, as several additional FoxO1 targets,
including Hnf4a, InsR, and Irs2, were unaffected (data not
shown).
With regard to lipid metabolism, we found decreases of Scd1
and Elovl3 (genes that are required for unsaturated fatty acid
synthesis and fatty acid elongation), the fatty acid transporter
Cd36, the liver hormone Fgf21, and Pparg (Figure 4B). TG
synthetic genes Srebf1, Chrebp and their targets, Fasn and
Acc1, were normal, whereas Pdk4 was increased, suggesting
that carbons are being diverted to lipid oxidation (Figure 4C).
These data, which are consistent with the observed decrease
of fatty acid synthesis and also with increased lipid oxidation,
might explain the decreases in plasma TG and FFA levels. To
understand whether these changes resulted from direct hepatic
effects of the Foxo1KR/KR mutation, we performed analyses of
basal and hormone-regulated gene expression in isolated
primary hepatocytes. The results were largely consistent with
those described above, supporting the conclusion that the KR
mutation affects hepatic gene expression in a cell-autonomous
manner (Figure S3).
We next analyzed adipose tissue. Unlike in liver, we detected
substantial increases of Chrebp and its targets, Fasn and Acc1,
as well as Elovl3 and Dgat2. Similar to the liver, expression of
Scd1 was decreased (Figure 4D). These findings suggest that
Foxo1KR/KR adipocytes are poised to synthesize TG from satu-
rated FFA (Guillou et al., 2010), possibly explaining the reduction
of plasma TG through increased deposition in adipocytes, which
is consistent with the increased weight gain of Foxo1KR/KR mice
when they were exposed to nutrient excess (see below). We
found no significant gene expression changes in skeletal muscle,
consistent with the fact that the latter is not a site of FoxO1
expression (data not shown) (Kitamura et al., 2007).
The KR Allele Fails to Exacerbate Insulin Resistance
on Predisposed Backgrounds
To explore in more detail the phenotype of Foxo1KR/KR mice, we
analyzed their metabolic profiles in response to nutritional and
genetic forms of insulin resistance. The prediction of theseInc.
Figure 3. Metabolic Data in Foxo1KR/KR Mice
(A) HOMA-IR values calculated from the data in Table S2.
(B) Pyruvate tolerance tests in WT and Foxo1KR/KR mice.
(C–E) Glucose infusion rates (C), endogenous glucose production under hyperinsulinemic conditions (D), and glycolysis during euglycemic hyperinsulinemic
clamps (E).
(F) Determination of TG content in lipoprotein fractions isolated by FPLC analysis.
(G) Basal and isoproterenol-stimulated glycerol release from primary cultures of epididymal fat pads. n =R 6 mice per group and each experiment. *p < 0.05;
**p < 0.01 by 2-way ANOVA. Data are presented as means ± SEM.
Cell Metabolism
In Vitro Effects of FoxO1 Acetylationstudies was that, if the KR allele acted as a bona fide gain-of-
function allele, it ought to exacerbate insulin resistance and
promote the transition to frank diabetes. In the first experiment,
we backcrossed Foxo1KR/KR mice on the C57BL6 background
and subjected them to high-fat diet (HFD). Foxo1KR/KR mice
consistently gained more weight than littermate controls (Fig-
ure 5A), due to increased fat mass (Figure 5B). Moreover,
adipose tissue of HFD-fed Foxo1KR/KRmice revealed substantial
increases of Elovl3 and Fasn (Figure S4), whereas liver TG andCell Mcholesterol content remained lower than wild-type littermates
(Figure S4). Contrary to our predictions, glycemia and intraperi-
toneal glucose tolerance were identical between Foxo1KR/KR
and controls (Figure 5C). There were no differences in plasma
leptin, adiponectin, and resistin levels (Table S3), whereas
TNF-a values were decreased and adipocyte Mcp1 expression
was lower (Figure S4), in the absence of histological changes
to adipose tissue between two genotypes (data not shown).
These findings are consistent with the possibility that adiposeetabolism 14, 587–597, November 2, 2011 ª2011 Elsevier Inc. 591
Figure 4. Gene Expression Analysis
(A–C) Hepatic expression of genes involved in glucose (A) and lipidmetabolism
(B and C) in 2-month-old male mice.
(D) Adipose expression of fatty acid and TG synthetic genes in the same
cohort. n =R 6 for each genotype. * = p < 0.05, ** = p < 0.01 by Student’s t test.
Data are presented as means ± SEM.
Cell Metabolism
In Vitro Effects of FoxO1 Acetylationtissue of Foxo1KR/KR mice is less proinflammatory and, thus,
might protect them against worsening glucose tolerance despite
increased body weight.
Likewise, when Foxo1KR/KR mice were intercrossed with
db/db mice, they tended to have greater body weights than592 Cell Metabolism 14, 587–597, November 2, 2011 ª2011 Elsevierdb/db controls (Figure 5D) but similar glucose (Figure 5E) and
insulin levels (Figure 5F) in the random-fed and 4-hr refed states.
Interestingly, fasting insulin levels were significantly higher in
Foxo1KR/KR:db/db compared to db/dbmice (Figure 5F). Moreover,
both genders of Foxo1KR/KR:db/db mice displayed worsening
glucose tolerance (Figures 5G and 5H).
The results in these two models indicate that the KR sub-
stitutions predispose to weight gain but hardly exacerbate
insulin resistance. To test the potential synergistic effects of
the Foxo1KR/KR mutation with insulin resistance more directly,
we introduced the KR allele on a background of nonobese
insulin resistance, insulin receptor haploinsufficient mice
(InsR+/) (Kido et al., 2000). Foxo1KR/KRInsR+/ double-mutant
mice showed a trend toward higher fasting glucose levels (Fig-
ure 5I) that was associated with increased fasting and fed insulin
levels (Figure 5J). However, glucose levels following an intraper-
itoneal glucose challenge were identical (Figure 5K), and the
hypoglycemic response to insulin was slightly impaired only
at late time points (R30 min) during intraperitoneal insulin
tolerance tests (data not shown).
In sum, these experiments indicate that the KR mutations
predispose to weight gain, but fail to cause overt diabetes in
strains predisposed to it by underlying insulin resistance.
Energy Balance in Foxo1KR/KR Mice
The above findings suggest that the KR allele selectively affects
energy balance. Therefore, we analyzed Foxo1KR/KR mice in
indirect calorimetry experiments. Food intake and body weight
in Foxo1KR/KR were similar to controls (Figures 6A and 6B). Con-
tinuous monitoring of respiratory exchanges and locomotor
activity in metabolic cages showed normal VO2 and locomotion
inFoxo1KR/KRmicebutdecreasedCO2generationand restingen-
ergy expenditure (Figures 6C–6E). These data indicate increased
reliance on lipids as an energy source, possibly explaining the
lower FFAandTG levels. To investigate differences in basalmeta-
bolic rate,wecompared theenergy expenditure required for loco-
motor activity in Foxo1KR/KR and control mice (Banks et al., 2008;
Ravussin et al., 1986). Foxo1KR/KR mice showed lower resting
energy expenditure in the face of unchanged activity (Figure 6F),
possibly reflecting altered substrate preference.
DISCUSSION
Functional Role of Acetylation in FoxO1 Function
There has been controversy on the role of FoxO1 acetylation.
Most (Daitoku et al., 2004; Kitamura et al., 2005; van der Heide
and Smidt, 2005; van der Horst et al., 2004) but not all reports
(Fukuoka et al., 2003; Motta et al., 2004; Yang et al., 2005) con-
clude that it decreases FoxO1 activity. Our data demonstrate
conclusively that acetylation is an ‘‘off’’ signal because
Foxo1KQ/KQ embryos are phenotypically undistinguishable from
Foxo1/ mutants (Furuyama et al., 2004; Hosaka et al., 2004).
The Foxo1KQ/KQ Mutant as a Model of Nutritional
Embryopathy
FoxO1 acetylation occurs in response to nutrient excess, (e.g.,
hyperglycemia) (Cheng et al., 2009; Kitamura et al., 2005).
Thus, the KQ allele can be construed to mimic the effects of
nutrient excess on embryonic development. In this regard, theInc.
Figure 5. Characterization of Foxo1KR/KR Mice in Dietary and Genetic Models of Insulin Resistance
(A–C) Body weight curves (A), body composition (B), and intraperitoneal glucose tolerance tests (C) in WT and Foxo1KR/KR mice during high-fat feeding.
(D–H) Body weight (D); 16 h fasting glucose levels (E); insulin levels in random fed, 16 h fasted, and 4 h refed mice (F); and glucose tolerance tests in male (G) and
(H) female db/db and Foxo1KR/KR;db/db mice.
(I–K) Fasting glucose levels (I); fed, fasted, and refed insulin levels (J); and glucose tolerance tests (K) in male InsR+/ and Foxo1KR/KR;InsR+/ (KR-InsR+/) mice.
n = 6-12 for each genotype and each experiment. * = p < 0.05, ** = p < 0.01 by 2-way ANOVA. Data are presented as means ± SEM.
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similarities with elusive aspects of diabetic embryopathy (Zabihi
and Loeken, 2010). Although we found no evidence of the char-
acteristic defects in neural tube formation of this condition in
Foxo1KQ/KQ mice, they display abnormalities in branchial arch
and cardiovascular development reminiscent of those found in
diabetic embryos (Morgan et al., 2008). Moreover, some of the
genes implicated in the pathogenesis of diabetic embryopathyCell Mhave also been shown to be FoxO1 targets (e.g., Gpx1) (Wentzel
et al., 2008).
Mixed Sensitivity and Resistance to Insulin
in Foxo1KR/KR Mutants
Foxo1KR/KR mutants display three striking metabolic subpheno-
types. (1) Altered hepatic glucose metabolism: the decreased
sensitivity to insulin-mediated suppressionofglucoseproductionetabolism 14, 587–597, November 2, 2011 ª2011 Elsevier Inc. 593
Figure 6. Energy Homeostasis Studies
(A–F) Food intake (A), body weight (B), energy expenditure as measured by
CO2-produced (VCO2) (C), respiratory exchange ratio (CO2-produced/O2
consumed) (RER) (D), locomotor activity (E), and metabolic efficiency plots (F)
in 2-month-old WT and Foxo1KR/KR mice maintained on standard chow diet.
n = 8 for each genotype and each experiment. * = p < 0.05 by 2-way ANOVA.
Data are presented as means ± SEM.
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594 Cell Metabolism 14, 587–597, November 2, 2011 ª2011 Elsevierlikely results fromabnormal regulation of FoxO1-dependent gene
expression and impaired regulation of FoxO1 localization.
Together with decreased rates of glycolysis, this phenotype
mirrors the defects seen in the diabetic liver (Bouche´ et al.,
2004). (2) Decreasedplasma lipid levels and hepatic lipid content:
the decreased expression of lipogenic genes and increased lipid
oxidation genes, together with a lower respiratory quotient, are
consistent with a state of preferential lipid usage. (3) Increased
weight gain under predisposing conditions without further
worsening of glucose metabolism: this finding is likely explained
by increased TG synthesis in adipose tissue, leading to preferen-
tial fat storage in adipocytes versus liver or other tissues.
To help interpret these seemingly disparate observations, it
behooves us to compare the subphenotypes linked to the
gain-of-function KR allele with those of mice expressing another
gain-of-function FoxO1 mutant: the phosphorylation-deficient,
but acetylation-competent, S253A (Table S3) (Nakae et al.,
2002). This mutation prevents insulin-dependent phosphoryla-
tion and results in a constitutively nuclear FoxO1 (Nakae et al.,
2001b). TheS253Amutant increases expression of FoxO1 target
genes in glucose production, as does the KR allele (Nakae et al.,
2002; Okamoto et al., 2006). However, the similarities end there
because the S253A mutant increases TG and cholesterol levels
(Altomonte et al., 2004), as well as VLDL secretion (Kamagate
et al., 2008), whereas the KR mutant has opposite effects.
Another phosphorylation-defective FoxO1 mutant, which bears
mutations of the three main phosphorylation sites (ADA) (Nakae
et al., 2001b), also promotes lipogenesis and hepatic lipid depo-
sition, while inhibiting lipid oxidation. However, unlike the KR
mutant, the ADA mutant increases Akt phosphorylation. Thus,
the increase in lipid synthesis in that instance is probably
secondary to Akt activation (Matsumoto et al., 2006). Although
comparisons between knockin mice and transgenics or adeno-
virus-mediated overexpression experiments require circum-
spect interpretation, this body of work indicates that theKR allele
has a distinctive gene expression signature. Without oversimpli-
fications, it can be said that it acts like a pure gain-of-function
mutant on hepatic glucogenesis and as a dominant negative
on lipid metabolism, lipoprotein turnover, and food intake.
The decrease in circulating plasma lipid levels is likely multi-
factorial, owing to increased expression of TG synthetic genes
in adipose tissue associated with changes in hepatic lipid
metabolism genes: the decreases in Scd1 and Pparg would be
expected to decrease hepatic lipid content (Gavrilova et al.,
2003; Gutie´rrez-Jua´rez et al., 2006), whereas decreases in Elovl3
can be associated with low VLDL (Zadravec et al., 2010). Inter-
estingly, FoxO1 has been shown to inhibit PPARg (Dowell
et al., 2003; Nakae et al., 2003), potentially accounting for
aspects of the gene expression profile. Indeed, mice lacking
either InsR or its main substrates, Irs1 and Irs2, in liver—two situ-
ations that can also be construed as FoxO1 gain of function—
phenocopy key aspects of the KR allele (Biddinger et al., 2008;
Dong et al., 2008). In sum, FoxO1 deacetylation promotes TG
deposition in adipose tissue and lipid catabolism in liver.
Mechanism and Physiologic Significance
of the KR Phenotype
These findings raise two interrelated questions: what is the
mechanism by which the KR allele alters the FoxO1-dependentInc.
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it recapitulate?
With regard to the first question, the gene expression data can
be explained by recalling the dual mechanism of action of
FoxO1: as a transcription factor and as a coregulator of gene
expression (Kitamura et al., 2007; Matsumoto et al., 2006; Ram-
aswamy et al., 2002). Pure transcriptional targets of FoxO1 (e.g.,
G6pc, Igfbp1, and Pgc1a) are equally induced by the deacety-
lated versus the dephosphorylated mutant, whereas genes in
which FoxO1 has the ability to act as a coregulator (e.g., Srebf1,
Pck1, and Gck) (Matsumoto et al., 2006) appear to be regulated
in a diverging manner by acetylation- versus phosphorylation-
defective mutants. We speculate that this is due to different
coactivator and corepressor complexes recruited by the two
mutants (Kitamura et al., 2006).
The physiologic significance of these observations is best
understood by considering that metabolic pathways are highly
regulated by acetylation and that protein deacetylation occurs
in response to prolonged fasting or calorie restriction (Schwer
and Verdin, 2008). Under these conditions, dampening the
FoxO1-dependent catabolic response can facilitate the transi-
tion from a physiologic fast (4–6 hr in a mouse) to a more pro-
longed state of nutrient deprivation. Thus, changes in gene
expression seen in Foxo1KR/KR mice could be construed as
mimicking the shift from a pure glucogenic state (short fast) to
a lipolytic state (prolonged fast), as demonstrated by the
increased glycerol release from isoproterenol-stimulated fat
pads (Figure 3F). In other words, acetylation becomes a fail-
safe mechanism to prevent excessive FoxO1 activity.
Relationship between FoxO1 Deacetylation and SirT1
We have reported that gain of function of the FoxO1 deacetylase
SirT1 mimics some effects of calorie restriction, promotes
insulin sensitivity, and causes FoxO1 deacetylation in mice
(SirBACO mice) (Banks et al., 2008). We had inferred that the
effects of SirT1 were mediated in large part through FoxO1.
The present analysis prompts a critical reevaluation of that infer-
ence. Foxo1KR/KR and SirBACO mice share limited metabolic
features. Thus, we conclude that the effects of SirT1 are largely
FoxO1-independent in mice. Conversely, it is likely that deacety-
lases other than SirT1 play a role in modulating FoxO1 function
(Mihaylova et al., 2011; Wang et al., 2011). The identification of
these proteins has important therapeutic implications.
EXPERIMENTAL PROCEDURES
Generation of Knock-in Mice
We amplified the Foxo1 locus around exon 2 from 129/SvEv DNA, using
Phusion polymerase (Finnzymes), and replaced the EcoR I/Hind III fragment
with sequences encoding either FoxO1-KR or FoxO1-KQ (Kitamura et al.,
2005). We selected homologous recombinants, using a floxed pGK-neomycin
cassette inserted 1 kb upstream of exon 2, and a diphtheria toxin-A cassette
and detection by Southern blotting of ES cell DNA digested with KpnI with a
probe external to the targeting vector. ES cell manipulationswere as described
(Accili et al., 1996) and were followed by intercrosses with ROSA26-cre trans-
genics to delete the neomycin cassette prior to breeding to homozygosity.
PCR genotyping primers are 50-GCACCTTCAGTCGCCGTCAA and 50-CCA
CAGGAGAATACAAGAGGAAGGC. The wild-type allele is 394-bp and the
knockin allele is 448 bp. Animals were backcrossed onto C57BL/6Jdb/+mice
[B6.BKS(D)-Leprdb/LeprJ, JAX stock 000697] for ten generations prior to diet
studies and indirect calorimetry.Cell MAdenovirus Generation and Cell Culture
We generated adenoviruses encoding WT-, KR- or KQ-FoxO1-GFP using
AdEasy (Stratagene), and obtained primary hepatocytes as described (Banks
et al., 2008). We carried out adenovirus transduction 4 hr after isolation.
Mice and Embryo Collection
We collected embryos from timed matings between Foxo1KQ/+ mice, con-
sidering 12 p.m. on the day of appearance of a vaginal plug as the beginning
of embryonic day (E) 0.5. We assessed litters at E9.5, E10.5, E11.5, and post-
natal day (P) 12, and carried out embryo dissections in cold PBS, using a dis-
secting microscope (Leica MZ8). We fixed embryos in 4% paraformaldehyde
(PFA), washed them three times in PBS, 1:1 PBS/MeOH, and 100% MeOH,
and performed immunostaining. We genotyped embryos using yolk sac
specimens.
Whole-mount Immunostaining
We carried out whole-mount immunohistochemistry with rat anti-mouse CD31
and platelet endothelial cell adhesion molecule-1 (PECAM-1) antibodies (BD
Biosciences). Briefly, after bleaching with MeOH:DMSO:H2O2 (4:1:1) for 5 hr,
we rehydrated embryos with 50% MeOH in PBT (PBS, 0.2% BSA, 0.5%
Triton-X), followed by one wash in PBT and five washes in PBSMT (PBS, 2%
non-fat milk powder, 0.5% Triton-X). We incubated embryos with primary
antibody in PBSMT, then washed and incubated themwith horseradish perox-
idase-conjugated antibody (sc-2005, Santa Cruz). We performed DAB staining
in PBT containing 0.08% NaCl, 0.25 mg/ml DAB, and 0.03% H2O2 for
20–60 min, followed by fixation in 4% PFA or fluorescent staining with
Cy3-donkey anti-rat secondary antibody (Jackson Immunoresearch). We
imaged embryos using a Nikon SMZ1500 microscope or a Zeiss LSM5 Exciter
confocal microscope.
Histology
For H&E histological analysis, we embedded embryos in octamer-binding
protein after fixation with 4% PFA and cryopreservation in 30% sucrose. We
obtained transverse frozen sections (8 mm) using a cryostat (Microm HM525,
Thermo Scientific) and imaged them using a Leica CTR6500 microscope.
Metabolic Characterization and Energy Balance Studies
We measured blood or plasma glucose using a glucose monitor (One Touch
Ultra, Lifescan); insulin, leptin, resistin, and adiponectin (Linco/Millipore) and
TNF–a (BD Biosciences) by ELISA; plasma triglyceride (Infinity); and choles-
terol and nonesterified fatty acids by colorimetric assays (Cholesterol E and
NEFA C, Wako Pure Chemicals). Glucose, insulin, and pyruvate tolerance
tests have been described (Matsumoto et al., 2007; Nakae et al., 2002). We
collected blood between 10:00 a.m. and 12:00 p.m. to reduce variability. For
lipoprotein separation, we pooled serum samples of six mice per genotype
and applied them to FPLC gel filtration on two Superose 6 columns in series
(Amersham Bioscience). We collected eluates in 0.5ml fractions at a flow
rate of 0.7 ml/min. We assayed TG and cholesterol from column eluates and
from liver extracts as described (Haeusler et al., 2010). To measure hepatic
glycogen content, we homogenized frozen liver in 6% perchloric acid,
adjusted to pH 6–7, with KOH followed by incubation with 1 mg/ml amyloglu-
cosidase (Sigma) in 0.2 M acetate (pH 4.8) and quantification of the glucose-
released (glycogen breakdown value) PCA value. We carried out hyperinsuli-
nemic-euglycemic clamp studies as described (Lin et al., 2009). We performed
indirect calorimetry using the Oxymax Comprehensive Lab Animal Monitoring
System (Columbus Instruments) and measured body composition with either
Piximus DEXA scanner (GE Healthcare) or NMR (Bruker Optics) (Banks
et al., 2008).
We used standard RNA extraction, real-time RT-PCR, and western blotting
procedures (Matsumoto et al., 2006). Primer sequences are available on
request. Antiacetylated-FoxO1 antibody was from Santa Cruz Biotechnology
(#sc-49437).
Statistical Analysis
All results are presented as mean ± SEM. We calculate p values by unpaired
Student’s t tests or 2-way ANOVA.etabolism 14, 587–597, November 2, 2011 ª2011 Elsevier Inc. 595
Cell Metabolism
In Vitro Effects of FoxO1 AcetylationSUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and four tables and can be
found online with this article at doi:10.1016/j.cmet.2011.09.012.
ACKNOWLEDGMENTS
Supported by NIH grants DK079496 (to A.S.B.), DK057539 and HL087123
(to D.A.), DK63608 (Columbia University Diabetes & Endocrinology Research
Center) and DK059635 (Yale MouseMetabolic Phenotyping Center). We thank
members of the Accili laboratory for helpful discussions of the data and critical
reading of the manuscript, Dr. Thomas Ludwig for the gift of the DT-A plasmid,
Dr. Lori Sussel for making her laboratory available for embryo analysis, and
Dr. Bruce Spiegelman for guidance and support.
Received: October 25, 2010
Revised: May 9, 2011
Accepted: September 9, 2011
Published online: November 1, 2011
REFERENCES
Accili, D., and Arden, K.C. (2004). FoxOs at the crossroads of cellular metab-
olism, differentiation, and transformation. Cell 117, 421–426.
Accili, D., Drago, J., Lee, E.J., Johnson, M.D., Cool, M.H., Salvatore, P., Asico,
L.D., Jose´, P.A., Taylor, S.I., and Westphal, H. (1996). Early neonatal death in
mice homozygous for a null allele of the insulin receptor gene. Nat. Genet. 12,
106–109.
Allen-Jennings, A.E., Hartman, M.G., Kociba, G.J., and Hai, T. (2001). The
roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver
dysfunction and defects in endocrine pancreas. J. Biol. Chem. 276, 29507–
29514.
Altomonte, J., Cong, L., Harbaran, S., Richter, A., Xu, J., Meseck, M., and
Dong, H.H. (2004). Foxo1 mediates insulin action on apoC-III and triglyceride
metabolism. J. Clin. Invest. 114, 1493–1503.
Banks, A.S., Kon, N., Knight, C., Matsumoto, M., Gutie´rrez-Jua´rez, R.,
Rossetti, L., Gu, W., and Accili, D. (2008). SirT1 gain of function increases
energy efficiency and prevents diabetes in mice. Cell Metab. 8, 333–341.
Biddinger, S.B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J.T., Alema´n,
J.O., Suzuki, R., Scapa, E.F., Agarwal, C., Carey, M.C., Stephanopoulos, G.,
et al. (2008). Hepatic insulin resistance is sufficient to produce dyslipidemia
and susceptibility to atherosclerosis. Cell Metab. 7, 125–134.
Bouche´, C., Serdy, S., Kahn, C.R., and Goldfine, A.B. (2004). The cellular fate
of glucose and its relevance in type 2 diabetes. Endocr. Rev. 25, 807–830.
Brunet, A., Sweeney, L.B., Sturgill, J.F., Chua, K.F., Greer, P.L., Lin, Y., Tran,
H., Ross, S.E., Mostoslavsky, R., Cohen, H.Y., et al. (2004). Stress-dependent
regulation of FOXO transcription factors by the SIRT1 deacetylase. Science
303, 2011–2015.
Cheng, Z., Guo, S., Copps, K., Dong, X., Kollipara, R., Rodgers, J.T., Depinho,
R.A., Puigserver, P., and White, M.F. (2009). Foxo1 integrates insulin signaling
with mitochondrial function in the liver. Nat. Med. 15, 1307–1311.
Daitoku, H., Hatta, M., Matsuzaki, H., Aratani, S., Ohshima, T., Miyagishi, M.,
Nakajima, T., and Fukamizu, A. (2004). Silent information regulator 2 potenti-
ates Foxo1-mediated transcription through its deacetylase activity. Proc.
Natl. Acad. Sci. USA 101, 10042–10047.
Dong, X.C., Copps, K.D., Guo, S., Li, Y., Kollipara, R., DePinho, R.A., and
White,M.F. (2008). Inactivation of hepatic Foxo1 by insulin signaling is required
for adaptive nutrient homeostasis and endocrine growth regulation. Cell
Metab. 8, 65–76.
Dowell, P., Otto, T.C., Adi, S., and Lane, M.D. (2003). Convergence of perox-
isome proliferator-activated receptor gamma and Foxo1 signaling pathways.
J. Biol. Chem. 278, 45485–45491.
Frescas, D., Valenti, L., and Accili, D. (2005). Nuclear trapping of the forkhead
transcription factor FoxO1 via Sirt-dependent deacetylation promotes expres-
sion of glucogenetic genes. J. Biol. Chem. 280, 20589–20595.596 Cell Metabolism 14, 587–597, November 2, 2011 ª2011 ElsevierFukuoka, M., Daitoku, H., Hatta, M., Matsuzaki, H., Umemura, S., and
Fukamizu, A. (2003). Negative regulation of forkhead transcription factor AFX
(Foxo4) by CBP-induced acetylation. Int. J. Mol. Med. 12, 503–508.
Furuyama, T., Kitayama, K., Shimoda, Y., Ogawa,M., Sone, K., Yoshida-Araki,
K., Hisatsune, H., Nishikawa, S., Nakayama, K., Nakayama, K., et al. (2004).
Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J. Biol. Chem. 279,
34741–34749.
Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J.J., Johnson, L., Dietz, K.R.,
Nicol, C.J., Vinson, C., Gonzalez, F.J., and Reitman, M.L. (2003). Liver perox-
isome proliferator-activated receptor gamma contributes to hepatic steatosis,
triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278,
34268–34276.
Guillou, H., Zadravec, D., Martin, P.G., and Jacobsson, A. (2010). The key roles
of elongases and desaturases in mammalian fatty acid metabolism: Insights
from transgenic mice. Prog. Lipid Res. 49, 186–199.
Gutie´rrez-Jua´rez, R., Pocai, A., Mulas, C., Ono, H., Bhanot, S., Monia, B.P.,
and Rossetti, L. (2006). Critical role of stearoyl-CoA desaturase-1 (SCD1) in
the onset of diet-induced hepatic insulin resistance. J. Clin. Invest. 116,
1686–1695.
Haeusler, R.A., Han, S., and Accili, D. (2010). Hepatic FoxO1 ablation exacer-
bates lipid abnormalities during hyperglycemia. J. Biol. Chem. 285, 26861–
26868.
Hosaka, T., Biggs, W.H., III, Tieu, D., Boyer, A.D., Varki, N.M., Cavenee, W.K.,
and Arden, K.C. (2004). Disruption of forkhead transcription factor (FOXO)
family members in mice reveals their functional diversification. Proc. Natl.
Acad. Sci. USA 101, 2975–2980.
Hribal, M.L., Nakae, J., Kitamura, T., Shutter, J.R., and Accili, D. (2003).
Regulation of insulin-like growth factor-dependent myoblast differentiation
by Foxo forkhead transcription factors. J. Cell Biol. 162, 535–541.
Imai, S., Armstrong, C.M., Kaeberlein, M., and Guarente, L. (2000).
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent
histone deacetylase. Nature 403, 795–800.
Kamagate, A., Qu, S., Perdomo, G., Su, D., Kim, D.H., Slusher, S., Meseck, M.,
and Dong, H.H. (2008). FoxO1 mediates insulin-dependent regulation of
hepatic VLDL production in mice. J. Clin. Invest. 118, 2347–2364.
Kido, Y., Burks, D.J., Withers, D., Bruning, J.C., Kahn, C.R., White, M.F., and
Accili, D. (2000). Tissue-specific insulin resistance inmice withmutations in the
insulin receptor, IRS-1, and IRS-2. J. Clin. Invest. 105, 199–205.
Kimura, K.D., Tissenbaum, H.A., Liu, Y., and Ruvkun, G. (1997). daf-2, an
insulin receptor-like gene that regulates longevity and diapause in
Caenorhabditis elegans. Science 277, 942–946.
Kitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs, W.H., III, Wright, C.V.,
White, M.F., Arden, K.C., and Accili, D. (2002). The forkhead transcription
factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell
growth. J. Clin. Invest. 110, 1839–1847.
Kitamura, Y.I., Kitamura, T., Kruse, J.P., Raum, J.C., Stein, R., Gu, W., and
Accili, D. (2005). FoxO1 protects against pancreatic beta cell failure through
NeuroD and MafA induction. Cell Metab. 2, 153–163.
Kitamura, T., Feng, Y., Kitamura, Y.I., Chua, S.C., Jr., Xu, A.W., Barsh, G.S.,
Rossetti, L., and Accili, D. (2006). Forkhead protein FoxO1 mediates Agrp-
dependent effects of leptin on food intake. Nat. Med. 12, 534–540.
Kitamura, T., Kitamura, Y.I., Funahashi, Y., Shawber, C.J., Castrillon, D.H.,
Kollipara, R., DePinho, R.A., Kitajewski, J., and Accili, D. (2007). A Foxo/
Notch pathway controls myogenic differentiation and fiber type specification.
J. Clin. Invest. 117, 2477–2485.
Lin, H.V., Plum, L., Ono, H., Gutie´rrez-Jua´rez, R., Shanabrough, M., Borok, E.,
Horvath, T.L., Rossetti, L., and Accili, D. (2009). Divergent regulation of energy
expenditure and hepatic glucose production by insulin receptor in agouti-
related protein and POMC neurons. Diabetes 59, 337–346.
Matsumoto, M., Han, S., Kitamura, T., and Accili, D. (2006). Dual role of
transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid
metabolism. J. Clin. Invest. 116, 2464–2472.Inc.
Cell Metabolism
In Vitro Effects of FoxO1 AcetylationMatsumoto, M., Pocai, A., Rossetti, L., Depinho, R.A., and Accili, D. (2007).
Impaired regulation of hepatic glucose production in mice lacking the forkhead
transcription factor Foxo1 in liver. Cell Metab. 6, 208–216.
Mihaylova, M.M., Vasquez, D.S., Ravnskjaer, K., Denechaud, P.D., Yu, R.T.,
Alvarez, J.G., Downes, M., Evans, R.M., Montminy, M., and Shaw, R.J.
(2011). Class IIa histone deacetylases are hormone-activated regulators of
FOXO and mammalian glucose homeostasis. Cell 145, 607–621.
Morgan, S.C., Relaix, F., Sandell, L.L., and Loeken, M.R. (2008). Oxidative
stress during diabetic pregnancy disrupts cardiac neural crest migration and
causes outflow tract defects. Birth Defects Res. A Clin. Mol. Teratol. 82,
453–463.
Motta, M.C., Divecha, N., Lemieux, M., Kamel, C., Chen, D., Gu, W., Bultsma,
Y., McBurney, M., and Guarente, L. (2004). Mammalian SIRT1 represses
forkhead transcription factors. Cell 116, 551–563.
Nakae, J., Kitamura, T., Ogawa, W., Kasuga, M., and Accili, D. (2001a). Insulin
regulation of gene expression through the forkhead transcription factor Foxo1
(Fkhr) requires kinases distinct from Akt. Biochemistry 40, 11768–11776.
Nakae, J., Kitamura, T., Silver, D.L., and Accili, D. (2001b). The forkhead
transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-
phosphatase expression. J. Clin. Invest. 108, 1359–1367.
Nakae, J., Biggs, W.H., III, Kitamura, T., Cavenee, W.K., Wright, C.V., Arden,
K.C., and Accili, D. (2002). Regulation of insulin action and pancreatic beta-
cell function by mutated alleles of the gene encoding forkhead transcription
factor Foxo1. Nat. Genet. 32, 245–253.
Nakae, J., Kitamura, T., Kitamura, Y., Biggs, W.H., III, Arden, K.C., and Accili,
D. (2003). The forkhead transcription factor Foxo1 regulates adipocyte
differentiation. Dev. Cell 4, 119–129.
Okamoto, H., Hribal, M.L., Lin, H.V., Bennett, W.R., Ward, A., and Accili, D.
(2006). Role of the forkhead protein FoxO1 in beta cell compensation to insulin
resistance. J. Clin. Invest. 116, 775–782.
Pfluger, P.T., Herranz, D., Velasco-Miguel, S., Serrano, M., and Tscho¨p, M.H.
(2008). Sirt1 protects against high-fat diet-induced metabolic damage. Proc.
Natl. Acad. Sci. USA 105, 9793–9798.
Plum, L., Lin, H.V., Dutia, R., Tanaka, J., Aizawa, K.S., Matsumoto, M., Kim,
A.J., Cawley, N.X., Paik, J.H., Loh, Y.P., et al. (2009). The obesity susceptibility
gene Cpe links FoxO1 signaling in hypothalamic pro-opiomelanocortin
neurons with regulation of food intake. Nat. Med. 15, 1195–1201.
Puigserver, P., Rhee, J., Donovan, J., Walkey, C.J., Yoon, J.C., Oriente, F.,
Kitamura, Y., Altomonte, J., Dong, H., Accili, D., and Spiegelman, B.M.Cell M(2003). Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-
1alpha interaction. Nature 423, 550–555.
Qiang, L., Banks, A.S., and Accili, D. (2010). Uncoupling of acetylation from
phosphorylation regulates FoxO1 function independent of its subcellular local-
ization. J. Biol. Chem. 285, 27396–27401.
Ramaswamy, S., Nakamura, N., Sansal, I., Bergeron, L., and Sellers, W.R.
(2002). A novel mechanism of gene regulation and tumor suppression by the
transcription factor FKHR. Cancer Cell 2, 81–91.
Ravussin, E., Lillioja, S., Anderson, T.E., Christin, L., and Bogardus, C. (1986).
Determinants of 24-hour energy expenditure in man. Methods and results
using a respiratory chamber. J. Clin. Invest. 78, 1568–1578.
Schwer, B., and Verdin, E. (2008). Conservedmetabolic regulatory functions of
sirtuins. Cell Metab. 7, 104–112.
Tissenbaum, H.A., and Guarente, L. (2001). Increased dosage of a sir-2 gene
extends lifespan in Caenorhabditis elegans. Nature 410, 227–230.
van der Heide, L.P., and Smidt, M.P. (2005). Regulation of FoxO activity by
CBP/p300-mediated acetylation. Trends Biochem. Sci. 30, 81–86.
van der Horst, A., Tertoolen, L.G., de Vries-Smits, L.M., Frye, R.A., Medema,
R.H., and Burgering, B.M. (2004). FOXO4 is acetylated upon peroxide stress
and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem. 279,
28873–28879.
Wang, B., Moya, N., Niessen, S., Hoover, H., Mihaylova, M.M., Shaw, R.J.,
Yates, J.R., III, Fischer, W.H., Thomas, J.B., and Montminy, M. (2011).
A hormone-dependent module regulating energy balance. Cell 145, 596–606.
Wentzel, P., Ga¨reskog, M., and Eriksson, U.J. (2008). Decreased cardiac
glutathione peroxidase levels and enhanced mandibular apoptosis in mal-
formed embryos of diabetic rats. Diabetes 57, 3344–3352.
Yang, Y., Hou, H., Haller, E.M., Nicosia, S.V., and Bai, W. (2005). Suppression
of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J.
24, 1021–1032.
Zabihi, S., and Loeken, M.R. (2010). Understanding diabetic teratogenesis:
where are we now and where are we going? Birth Defects Res. A Clin. Mol.
Teratol. 88, 779–790.
Zadravec, D., Brolinson, A., Fisher, R.M., Carneheim, C., Csikasz, R.I.,
Bertrand-Michel, J., Bore´n, J., Guillou, H., Rudling, M., and Jacobsson, A.
(2010). Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice
leads to constrained lipid storage and resistance to diet-induced obesity.
FASEB J. 24, 4366–4377.etabolism 14, 587–597, November 2, 2011 ª2011 Elsevier Inc. 597
